Page 2 - Vercise Genus News Today

Visiongain has published a new report entitled Neurotech Devices Market 2023-2033. It includes profiles of Neurotech Devices and Forecasts, Market Segment...

BSX earnings call for the period ending June 30, 2022.

BSX earnings call for the period ending June 30, 2022.

Boston Scientific today announced it received FDA approval for its Vercise Neural Navigator with StimView XT.

BSX earnings call for the period ending September 30, 2021.

Boston Scientific Announces Results For First Quarter 2021 News provided by Share this article Share this article MARLBOROUGH, Mass., April 28, 2021 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $2.752 billion during the first quarter of 2021. This represents growth of 8.2 percent on a reported basis, 5.6 percent on an operational 1 basis and 5.9 percent on an organic 2 basis, all compared to the prior year period. The company reported GAAP net income availab...

Henry Ford first in the U.S. to offer FDA-approved DBS system to treat Parkinsons disease The Parkinsons Disease and Movement Disorder Center at Henry Ford Health System was the first in the United States to offer a new FDA-approved device to help treat the symptoms of Parkinsons disease. Neurosurgeon Jason Schwalb, M.D. surgically implanted the Vercise Genus™ Deep Brain Stimulation (DBS) System, which stimulates a targeted region of the brain through - implanted leads that are placed in the ...

 E-Mail IMAGE: Jason Schwalb, M.D., just before surgically implanting the first Vercise Genus™ Deep Brain Stimulation (DBS) System in the United States. view more  Credit: Henry Ford Health System DETROIT (Feb. 18, 2021) - The Parkinsons Disease and Movement Disorder Center at Henry Ford Health System was the first in the United States to offer a new FDA-approved device to help treat the symptoms of Parkinsons disease. Neurosurgeon Jason Schwalb, M.D. surgically implanted the Vercis...

Boston Scientific Announces Results For Fourth Quarter And Full Year 2020 News provided by Share this article Share this article MARLBOROUGH, Mass., Feb. 3, 2021 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $2.708 billion during the fourth quarter of 2020. This represents a decline of (6.8) percent on a reported basis, (8.3) percent on an operational 1 basis and (8.0) percent on an organic 2 basis, all compared to the prior year period. Included within organi...

Operator Good morning, and welcome to the Boston Scientific Fourth Quarter 2020 Financial Results Conference Call. [Operator Instructions] I would now like to turn the conference over to Susan Lisa, Vice President, Investor Relations. Please go ahead. Susie Lisa -- Vice President, Investor Relations Thank you, Andrew. Good morning, everyone, and thanks for joining us. With me on todays call are Mike Mahoney, Chairman and Chief Executive Officer and Dan Brennan, Executive Vice President and Chi...